Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Neuropharmacology
  4. Volume 22, Issue 14
  5. Article
Volume 22, Issue 14
  • ISSN: 1570-159X
  • E-ISSN: 1875-6190

Abstract

There is much debate about continuing antipsychotic medication in patients who need it when they become pregnant because benefits must be weighed against potential teratogenic and malformation effects related to antipsychotics themselves. To address this, we conducted a systematic review on the PubMed, PsycINFO and CINHAL databases and the ClinicalTrials.gov register using the following strategy: (toxicity OR teratogenicity OR malformation* OR “birth defect*” OR “congenital abnormality” OR “congenital abnormalities” OR “brain changes” OR “behavioral abnormalities” OR “behavioral abnormalities”) AND antipsychotic* AND (pregnancy OR pregnant OR lactation OR delivery OR prenatal OR perinatal OR post-natal OR puerperium) on September 27, 2023. We found 38 studies to be eligible. The oldest was published in 1976, while most articles were recent. Most studies concluded that the antipsychotics, especially the second-generation antipsychotics, were devoid of teratogenic potential, while few studies were inconclusive and recommended replication. Most authoritative articles were from the Boston area, where large databases were implemented to study the malformation potential of psychiatric drugs. Other reliable databases are from Northern European registers. Overall conclusions are that antipsychotics are no more related to malformations than the disorders themselves; most studies recommend that there are no reasons to discontinue antipsychotic medications in pregnancy.

© 2024 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cn/10.2174/1570159X22666240516151449
2024-12-01
2024-11-26

  • From This Site

    /content/journals/cn/10.2174/1570159X22666240516151449
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. DaviesC. SegreG. EstradéA. RaduaJ. De MicheliA. ProvenzaniU. OliverD. Salazar de PabloG. Ramella-CravaroV. BesozziM. DazzanP. MieleM. CaputoG. SpallarossaC. CrosslandG. IlyasA. SpadaG. PolitiP. MurrayR.M. McGuireP. Fusar-PoliP. Prenatal and perinatal risk and protective factors for psychosis: A systematic review and meta-analysis.Lancet Psychiatry20207539941010.1016/S2215‑0366(20)30057‑2 32220288
     [Google Scholar]
  2. HowardL.M. KhalifehH. Perinatal mental health: A review of progress and challenges.World Psychiatry202019331332710.1002/wps.20769 32931106
     [Google Scholar]
  3. OrsoliniL. SceusaF. PompiliS. MauroA. SalviV. VolpeU. Severe and persistent mental illness (SPMI) in pregnancy and breastfeeding: Focus on second-generation long acting injectable antipsychotics.Expert Opin. Drug Saf.202120101207122410.1080/14740338.2021.1928634 33966552
     [Google Scholar]
  4. WesselooR. KampermanA.M. BerginkV. PopV.J.M. Thyroid peroxidase antibodies during early gestation and the subsequent risk of first-onset postpartum depression: A prospective cohort study.J. Affect. Disord.201822539940310.1016/j.jad.2017.08.058 28850854
     [Google Scholar]
  5. ValdimarsdóttirU. HultmanC.M. HarlowB. CnattingiusS. SparénP. Psychotic illness in first-time mothers with no previous psychiatric hospitalizations: A population-based study.PLoS Med.200962e100001310.1371/journal.pmed.1000013 19209952
     [Google Scholar]
  6. O’HaraM.W. WisnerK.L. Perinatal mental illness: Definition, description and aetiology.Best Pract. Res. Clin. Obstet. Gynaecol.201428131210.1016/j.bpobgyn.2013.09.002 24140480
     [Google Scholar]
  7. CuomoA. GoracciA. FagioliniA. Aripiprazole use during pregnancy, peripartum and lactation. A systematic literature search and review to inform clinical practice.J. Affect. Disord.201822822923710.1016/j.jad.2017.12.021 29275156
     [Google Scholar]
  8. WinansE.A. Antipsychotics and Breastfeeding.J. Hum. Lact.200117434434710.1177/089033440101700408 11847903
     [Google Scholar]
  9. Conejo-GalindoJ. Sanz-GiancolaA. Álvarez-MonM.Á. OrtegaM.Á. Gutiérrez-RojasL. LaheraG. Postpartum relapse in patients with bipolar disorder.J. Clin. Med.20221114397910.3390/jcm11143979 35887743
     [Google Scholar]
  10. EdinoffA.N. SathivadivelN. McNeilS.E. LyA.I. KweonJ. KelkarN. CornettE.M. KayeA.M. KayeA.D. Antipsychotic use in pregnancy: Patient mental health challenges, teratogenicity, pregnancy complications, and postnatal risks.Neurol. Int.2022141627410.3390/neurolint14010005 35076595
     [Google Scholar]
  11. Munk-OlsenT. LaursenT.M. MendelsonT. PedersenC.B. MorsO. MortensenP.B. Risks and predictors of readmission for a mental disorder during the postpartum period.Arch. Gen. Psychiatry200966218919510.1001/archgenpsychiatry.2008.528 19188541
     [Google Scholar]
  12. SpragueJ. WisnerK.L. BogenD.L. Pharmacotherapy for depression and bipolar disorder during lactation: A framework to aid decision making.Semin. Perinatol.202044315122410.1016/j.semperi.2020.151224 32199600
     [Google Scholar]
  13. McAllister-WilliamsR.H. BaldwinD.S. CantwellR. EasterA. GilvarryE. GloverV. GreenL. GregoireA. HowardL.M. JonesI. KhalifehH. Lingford-HughesA. McDonaldE. MicaliN. ParianteC.M. PetersL. RobertsA. SmithN.C. TaylorD. WieckA. YatesL.M. YoungA.H. British association for psychopharmacology consensus guidance on the use of psychotropic medication preconception, in pregnancy and postpartum 2017.J. Psychopharmacol.201731551955210.1177/0269881117699361 28440103
     [Google Scholar]
  14. PageM.J. McKenzieJ.E. BossuytP.M. BoutronI. HoffmannT.C. MulrowC.D. ShamseerL. TetzlaffJ.M. AklE.A. BrennanS.E. ChouR. GlanvilleJ. GrimshawJ.M. HróbjartssonA. LaluM.M. LiT. LoderE.W. Mayo-WilsonE. McDonaldS. McGuinnessL.A. StewartL.A. ThomasJ. TriccoA.C. WelchV.A. WhitingP. MoherD. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.BMJ202137271n7110.1136/bmj.n71 33782057
     [Google Scholar]
  15. ROBINS-E Development Group. HigginsJ. MorganR. RooneyA. TaylorK. ThayerK. SilvaR . LemerisC. AklA. ArroyaveW. BatesonT. BerkmanN. DemersP. ForastiereF. GlennB. HróbjartssonA. KirraneE. LaKindJ. LubenT. LunnR. McAleenanA. McGuinnessL. MeerpohlJ. MehtaS. NachmanR. ObbagyJ. O'ConnorA. RadkeE. SavovićJ. Schubauer-BeriganM. SchwinglP. SchunemannH. SheaB. SteenlandK. StewartT. StraifK. TillingK. VerbeekV. VermeulenR. ViswanathanM. ZahmS. SterneJ. Risk Of Bias In Non-randomized Studies of Exposure (ROBINS-E). Launch version, 20 June 2023Available from: https://www.riskofbias.info/welcome/robins-e-tool (assessed on August 25, 2023.)
     [Google Scholar]
  16. RiederR.O. RosenthalD. WenderP. BlumenthalH. The offspring of schizophrenics. Fetal and neonatal deaths.Arch. Gen. Psychiatry197532220021110.1001/archpsyc.1975.01760200064006 234727
     [Google Scholar]
  17. MilkovichL. van den BergB.J. An evaluation of the teratogenicity of certain antinauseant drugs.Am. J. Obstet. Gynecol.1976125224424810.1016/0002‑9378(76)90601‑3 773181
     [Google Scholar]
  18. McKeigueP.M. LammS.H. LinnS. KutcherJ.S. Bendectin and birth defects: I. A meta‐analysis of the epidemiologic studies.Teratology1994501273710.1002/tera.1420500105 7974252
     [Google Scholar]
  19. SloneD. SiskindV. HeinonenO.P. MonsonR.R. KaufmanD.W. ShapiroS. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score.Am. J. Obstet. Gynecol.1977128548648810.1016/0002‑9378(77)90029‑1 879206
     [Google Scholar]
  20. GodetP.F. Marie-CardineM. Neuroleptiques, schizophrénie et grossesse. Etude épidémiologique et tératologique.Encephale1991176543547 1687216
     [Google Scholar]
  21. SharmaJ.B. SharmaS. Role of thioridazine in unexplained infertility.Int. J. Gynaecol. Obstet.1992371374110.1016/0020‑7292(92)90975‑O 1346599
     [Google Scholar]
  22. GoldsteinD.J. CorbinL.A. FungM.C. Olanzapine-exposed pregnancies and lactation: Early experience.J. Clin. Psychopharmacol.200020439940310.1097/00004714‑200008000‑00002 10917399
     [Google Scholar]
  23. Diav-CitrinO. ShechtmanS. OrnoyS. ArnonJ. SchaeferC. GarbisH. ClementiM. OrnoyA. Safety of haloperidol and penfluridol in pregnancy: A multicenter, prospective, controlled study.J. Clin. Psychiatry200566331732210.4088/JCP.v66n0307 15766297
     [Google Scholar]
  24. McKennaK. KorenG. TetelbaumM. WiltonL. ShakirS. Diav-CitrinO. LevinsonA. ZipurskyR.B. EinarsonA. Pregnancy outcome of women using atypical antipsychotic drugs: A prospective comparative study.J. Clin. Psychiatry200566444444910.4088/JCP.v66n0406 15816786
     [Google Scholar]
  25. ReisM. KällénB. Maternal use of antipsychotics in early pregnancy and delivery outcome.J. Clin. Psychopharmacol.200828327928810.1097/JCP.0b013e318172b8d5 18480684
     [Google Scholar]
  26. BabuG.N. DesaiG. TippeswamyH. ChandraP.S. Birth weight and use of olanzapine in pregnancy: A prospective comparative study.J. Clin. Psychopharmacol.201030333133210.1097/JCP.0b013e3181db8734 20473073
     [Google Scholar]
  27. GiladO. MerlobP. StahlB. KlingerG. Outcome of infants exposed to olanzapine during breastfeeding.Breastfeed. Med.201162555810.1089/bfm.2010.0027 21034242
     [Google Scholar]
  28. HabermannF. FritzscheJ. FuhlbrückF. WackerE. AllignolA. Weber-SchoendorferC. MeisterR. SchaeferC. Atypical antipsychotic drugs and pregnancy outcome: A prospective, cohort study.J. Clin. Psychopharmacol.201333445346210.1097/JCP.0b013e318295fe12 23764684
     [Google Scholar]
  29. SadowskiA. TodorowM. Yazdani BrojeniP. KorenG. NulmanI. Pregnancy outcomes following maternal exposure to second-generation antipsychotics given with other psychotropic drugs: A cohort study.BMJ Open201337e00306210.1136/bmjopen‑2013‑003062 23852139
     [Google Scholar]
  30. BelletF. BeyensM.N. BernardN. BeghinD. ElefantE. VialT. Exposure to aripiprazole during embryogenesis: A prospective multicenter cohort study.Pharmacoepidemiol. Drug Saf.201524436838010.1002/pds.3749 25683615
     [Google Scholar]
  31. CohenL.S. VigueraA.C. McInerneyK.A. FreemanM.P. SosinskyA.Z. MoustafaD. MarfurtS.P. KwiatkowskiM.A. MurphyS.K. FarrellA.M. ChitayatD. Hernández-DíazS. Reproductive safety of second-generation antipsychotics: Current data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics.Am. J. Psychiatry2016173326327010.1176/appi.ajp.2015.15040506 26441156
     [Google Scholar]
  32. MontastrucF. SalvoF. ArnaudM. BégaudB. ParienteA. Signal of gastrointestinal congenital malformations with antipsychotics after minimising competition bias: A disproportionality analysis using data from Vigibase.Drug Saf.201639768969610.1007/s40264‑016‑0413‑1 26961536
     [Google Scholar]
  33. PetersenI. McCreaR.L. SammonC.J. OsbornD.P.J. EvansS.J. CowenP.J. FreemantleN. NazarethI. Risks and benefits of psychotropic medication in pregnancy: Cohort studies based on UK electronic primary care health records.Health Technol. Assess.20162023117610.3310/hta20230 27029490
     [Google Scholar]
  34. PetersenI. SammonC.J. McCreaR.L. OsbornD.P.J. EvansS.J. CowenP.J. NazarethI. Risks associated with antipsychotic treatment in pregnancy: Comparative cohort studies based on electronic health records.Schizophr. Res.20161762-334935610.1016/j.schres.2016.07.023 27484686
     [Google Scholar]
  35. HuybrechtsK.F. Hernández-DíazS. PatornoE. DesaiR.J. MogunH. DejeneS.Z. CohenJ.M. PanchaudA. CohenL. BatemanB.T. Antipsychotic use in pregnancy and the risk for congenital malformations.JAMA Psychiatry201673993894610.1001/jamapsychiatry.2016.1520 27540849
     [Google Scholar]
  36. HattersF.S. Moller-OlsenC. PrakashC. NorthA. Atypical antipsychotic use and outcomes in an urban maternal mental health service.Int. J. Psychiatry Med.201651652153310.1177/0091217417696739 28629296
     [Google Scholar]
  37. ShinY.J. ChoiJ.S. AhnH.K. RyuH.M. KimM.Y. HanJ.Y. Pregnancy outcomes in women reporting ingestion of levosulpiride in early pregnancy.J. Obstet. Gynaecol.201737899299510.1080/01443615.2017.1312307 28631490
     [Google Scholar]
  38. OnkenM. MickI. SchaeferC. Paliperidone and pregnancy: An evaluation of the German Embryotox database.Arch. Women Ment. Health201821665766210.1007/s00737‑018‑0828‑z 29569043
     [Google Scholar]
  39. GalballyM. FrayneJ. WatsonS.J. SnellenM. Aripiprazole and pregnancy: A retrospective, multicentre study.J. Affect. Disord.201823859359610.1016/j.jad.2018.06.004 29957476
     [Google Scholar]
  40. CohenL.S. Góez-MogollónL. SosinskyA.Z. SavellaG.M. VigueraA.C. ChitayatD. Hernández-DíazS. FreemanM.P. Risk of major malformations in infants following first-trimester exposure to quetiapine.Am. J. Psychiatry2018175121225123110.1176/appi.ajp.2018.18010098 30111186
     [Google Scholar]
  41. AndersonK.N. AilesE.C. LindJ.N. BroussardC.S. BitskoR.H. FriedmanJ.M. BoboW.V. ReefhuisJ. TinkerS.C. Atypical antipsychotic use during pregnancy and birth defect risk: National Birth Defects Prevention Study, 1997–2011.Schizophr. Res.2020215818810.1016/j.schres.2019.11.019 31761471
     [Google Scholar]
  42. EllfolkM. LeinonenM.K. GisslerM. Lahesmaa-KorpinenA.M. SaastamoinenL. NurminenM.L. MalmH. Second-generation antipsychotics and pregnancy complications.Eur. J. Clin. Pharmacol.202076110711510.1007/s00228‑019‑02769‑z 31680189
     [Google Scholar]
  43. EllfolkM. LeinonenM.K. GisslerM. Kiuru-KuhlefeltS. SaastamoinenL. MalmH. Second-generation antipsychotic use during pregnancy and risk of congenital malformations.Eur. J. Clin. Pharmacol.202177111737174510.1007/s00228‑021‑03169‑y 34100993
     [Google Scholar]
  44. FreemanM.P. VigueraA.C. Góez-MogollónL. YoungA.V. CaplinP.S. McElhenyS.A. ChurchT.R. ChitayatD. Hernández-DíazS. CohenL.S. Reproductive safety of aripiprazole: Data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics.Arch. Women Ment. Health202124465966710.1007/s00737‑021‑01115‑6 33710399
     [Google Scholar]
  45. VigueraA.C. FreemanM.P. Góez-MogollónL. SosinskyA.Z. McElhenyS.A. ChurchT.R. YoungA.V. CaplinP.S. ChitayatD. Hernández-DíazS. CohenL.S. Reproductive safety of second-generation antipsychotics: updated data from the massachusetts general hospital national pregnancy registry for atypical antipsychotics.J. Clin. Psychiatry, 202182420m1374510.4088/JCP.20m13745
     [Google Scholar]
  46. NguyenT. FrayneJ. WatsonS. LebedevsT. TeohS. GalballyM. Long-acting injectable antipsychotic treatment during pregnancy: Outcomes for women at a tertiary maternity hospital.Psychiatry Res.202231311461410.1016/j.psychres.2022.114614 35576628
     [Google Scholar]
  47. YakuwaN. TakahashiK. AnzaiT. ItoN. GotoM. KoinumaS. UnoC. SuzukiT. WatanabeO. YamataniA. MurashimaA. Pregnancy outcomes with exposure to second-generation antipsychotics during the first trimester. Clin. Psychiatry202283421m1408110.4088/JCP.21m14081
     [Google Scholar]
  48. HálfdánarsonÓ. CohenJ.M. KarlstadØ. CestaC.E. BjørkM.H. HåbergS.E. EinarsdóttirK. FuruK. GisslerM. HjellvikV. KielerH. LeinonenM.K. NørgaardM. Öztürk EsenB. UlrichsenS.P. ReutforsJ. ZoegaH. Antipsychotic use in pregnancy and risk of attention/deficit-hyperactivity disorder and autism spectrum disorder: A Nordic cohort study.Evid. Based Ment. Health2022252546210.1136/ebmental‑2021‑300311 34810174
     [Google Scholar]
  49. StraubL. Hernández-DíazS. BatemanB.T. WisnerK.L. GrayK.J. PennellP.B. LesterB. McDougleC.J. SuarezE.A. ZhuY. ZakoulH. MogunH. HuybrechtsK.F. Association of antipsychotic drug exposure in pregnancy with risk of neurodevelopmental disorders: A National Birth Cohort Study.JAMA Intern. Med.2022182552253310.1001/jamainternmed.2022.0375 35343998
     [Google Scholar]
  50. HuybrechtsK.F. StraubL. KarlssonP. PazzagliL. FuruK. GisslerM. Hernandez-DiazS. NørgaardM. ZoegaH. BatemanB.T. CestaC.E. CohenJ.M. LeinonenM.K. ReutforsJ. SelmerR.M. SuarezE.A. UlrichsenS.P. KielerH. Association of in utero antipsychotic medication exposure with risk of congenital malformations in Nordic countries and the US.JAMA Psychiatry202380215616610.1001/jamapsychiatry.2022.4109 36477338
     [Google Scholar]
  51. CohenL.S. ChurchT.R. FreemanM.P. GaccioneP. CaplinP.S. KobylskiL.A. ArakelianM. RossaE.T. ChitayatD. Hernández-DíazS. VigueraA.C. Reproductive safety of lurasidone and quetiapine: Update from the national pregnancy registry for psychiatric medications.J. Womens Health 202332445246210.1089/jwh.2022.0310 36716275
     [Google Scholar]
  52. VigueraA.C. FreemanM.P. KobylskiL.A. RossaE.T. GaccioneP. ChitayatD. Hernández-DíazS. CohenL.S. Risk of major malformations following first-trimester exposure to olanzapine: Preliminary data from the Massachusetts General Hospital National Pregnancy Registry for Psychiatric Medications.J. Clin. Psychopharmacol.202343210611210.1097/JCP.0000000000001665 36825887
     [Google Scholar]
  53. LiuX. KoldingL. MomenN. GasseC. PedersenL.H. Maternal antipsychotic use during pregnancy and congenital malformations.Am. J. Obstet. Gynecol. MFM20235610095010.1016/j.ajogmf.2023.100950 37015311
     [Google Scholar]
  54. SchrijverL. RobakisT.K. KampermanA.M. BijmaH. HonigA. van KampI.L. HoogendijkW.J.G. BerginkV. PoelsE.M.P. Neurodevelopment in school‐aged children after intrauterine exposure to antipsychotics.Acta Psychiatr. Scand.20231471435310.1111/acps.13517 36333825
     [Google Scholar]
  55. Idänpään-HeikkiläJ. AlhavaE. OlkinuoraM. PalvaI. Letter: Clozapine and agranulocytosis.Lancet1975306793561110.1016/S0140‑6736(75)90206‑8 51442
     [Google Scholar]
  56. MeltzerH.Y. BastaniB. RamirezL. MatsubaraS. Clozapine: New research on efficacy and mechanism of action.Eur. Arch. Psychiatry Neurol. Sci.19892385-633233910.1007/BF00449814 2569975
     [Google Scholar]
  57. PerraultG. SchoemakerH. ScattonB. Place de l’amisulpride dans la classe des neuroleptiques atypiques.Encephale199622Spec No 238 8767034
     [Google Scholar]
  58. CitromeL. HoltR.I.G. WalkerD.J. HoffmannV.P. Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.Clin. Drug Investig.201131745548210.2165/11589060‑000000000‑00000 21495734
     [Google Scholar]
  59. LambertT.J.R. Switching to aripiprazole from olanzapine leads to weight loss in overweight people with schizophrenia or schizoaffective disorder.Evid. Based Ment. Health20091225010.1136/ebmh.12.2.50 19395609
     [Google Scholar]
  60. TyrrellJ. RichmondR.C. PalmerT.M. FeenstraB. RangarajanJ. MetrustryS. CavadinoA. PaternosterL. ArmstrongL.L. De SilvaN.M.G. WoodA.R. HorikoshiM. GellerF. MyhreR. BradfieldJ.P. Kreiner-MøllerE. HuikariV. PainterJ.N. HottengaJ.J. AllardC. BerryD.J. BouchardL. DasS. EvansD.M. HakonarsonH. HayesM.G. HeikkinenJ. HofmanA. KnightB. LindP.A. McCarthyM.I. McMahonG. MedlandS.E. MelbyeM. MorrisA.P. NodzenskiM. ReichetzederC. RingS.M. SebertS. SengpielV. SørensenT.I.A. WillemsenG. de GeusE.J.C. MartinN.G. SpectorT.D. PowerC. JärvelinM.R. BisgaardH. GrantS.F.A. NohrE.A. JaddoeV.W. JacobssonB. MurrayJ.C. HocherB. HattersleyA.T. ScholtensD.M. Davey SmithG. HivertM.F. FelixJ.F. HyppönenE. LoweW.L.Jr FraylingT.M. LawlorD.A. FreathyR.M. Genetic evidence for causal relationships between maternal obesity-related traits and birth weight.JAMA2016315111129114010.1001/jama.2016.1975 26978208
     [Google Scholar]
  61. SchmidtM. SchmidtS.A.J. SandegaardJ.L. EhrensteinV. PedersenL. SørensenH.T. The danish national patient registry: A review of content, data quality, and research potential.Clin. Epidemiol.2015744949010.2147/CLEP.S91125 26604824
     [Google Scholar]
  62. LyngeE. SandegaardJ.L. ReboljM. The danish national patient register. Scand. J. Public Health,2011397_suppl)(Suppl.303310.1177/140349481140148221775347
     [Google Scholar]
  63. CohenL.S. VigueraA.C. McInerneyK.A. KwiatkowskiM.A. MurphyS.K. LemonE.L. Hernández-DíazS. Establishment of the national pregnancy registry for atypical antipsychotics.J. Clin. Psychiatry201576798698910.4088/JCP.14br09418 25939066
     [Google Scholar]
  64. VariI.S. BalkauB. KettanehA. AndréP. TichetJ. FumeronF. CacesE. MarreM. GrandchampB. DucimetièreP. Ferritin and transferrin are associated with metabolic syndrome abnormalities and their change over time in a general population: Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR).Diabetes Care20073071795180110.2337/dc06‑2312 17416791
     [Google Scholar]
  65. MusengaA. SaracinoM. SaniG. RaggiM. Antipsychotic and antiepileptic drugs in bipolar disorder: The importance of therapeutic drug monitoring.Curr. Med. Chem.200916121463148110.2174/092986709787909604 19355900
     [Google Scholar]
  66. WangZ. BrauerR. ManK.K.C. AlfagehB. MongkhonP. WongI.C.K. Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: A systematic review and meta‐analysis.Br. J. Clin. Pharmacol.202187114101412310.1111/bcp.14839 33772841
     [Google Scholar]
  67. HillemacherT. SimenS. RehmeM.K. FrielingH. Antipsychotics during pregnancy: A systematic review.Nervenarzt202192549450010.1007/s00115‑020‑01006‑8
     [Google Scholar]
  68. GentileS. Antipsychotic therapy during early and late pregnancy. A systematic review.Schizophr. Bull.201036351854410.1093/schbul/sbn107 18787227
     [Google Scholar]
  69. GentileS. FuscoM.L. Schizophrenia and motherhood.Psychiatry Clin. Neurosci.201973737638510.1111/pcn.12856 31026107
     [Google Scholar]
  70. OyebodeF. RastogiA. BerrisfordG. CocciaF. Psychotropics in pregnancy: Safety and other considerations.Pharmacol. Ther.20121351717710.1016/j.pharmthera.2012.03.008 22483705
     [Google Scholar]
  71. CoughlinC.G. BlackwellK.A. BartleyC. HayM. YonkersK.A. BlochM.H. Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy.Obstet. Gynecol.201512551224123510.1097/AOG.0000000000000759 25932852
     [Google Scholar]
  72. CentorrinoF. FogartyK.V. SaniG. SalvatoreP. CincottaS.L. HennenJ. GuzzettaF. TalamoA. SaadehM.G. BaldessariniR.J. Use of combinations of antipsychotics: McLean Hospital inpatients, 2002.Hum. Psychopharmacol.200520748549210.1002/hup.719 16116665
     [Google Scholar]
  73. CentorrinoF. FogartyK.V. SaniG. SalvatoreP. CimbolliP. BaldessariniR.J. Antipsychotic drug use: McLean Hospital, 2002.Hum. Psychopharmacol.200520535535810.1002/hup.700 15957153
     [Google Scholar]
/content/journals/cn/10.2174/1570159X22666240516151449
Loading
Is Antipsychotic Drug Use During Pregnancy Associated with Increased Malformation Rates and Worsening of Maternal and Infant Outcomes? A Systematic Review
Curr. Neuropharmacol. 22, 2402 (2024); https://doi.org/10.2174/1570159X22666240516151449
/content/journals/cn/10.2174/1570159X22666240516151449
/content/journals/cn/10.2174/1570159X22666240516151449
Loading

Data & Media loading...

Supplements

file format download Download

  • Article Type:     Review Article
Keyword(s): antipsychotic drugs; lactation; major; malformations; Pregnancy; second generation antipsychotics; teratogenicity

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test